Search

Your search keyword '"Mok, T.S.K."' showing total 44 results
Start Over Author "Mok, T.S.K." Publisher elsevier b.v.
44 results on '"Mok, T.S.K."'

2. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.

Author

Mok, T.S.K., Lopes, G., Cho, B.C., Kowalski, D.M., Kasahara, K., Wu, Y.-L., de Castro, G., Turna, H.Z., Cristescu, R., Aurora-Garg, D., Loboda, A., Lunceford, J., Kobie, J., Ayers, M., Pietanza, M.C., Piperdi, B., and Herbst, R.S.

Subjects
*CLINICAL trials, *TREATMENT effectiveness, *NON-small-cell lung carcinoma, *PEMBROLIZUMAB, *CANCER chemotherapy
Abstract

We evaluated whether tissue tumor mutational burden (tTMB) and STK11 , KEAP1 , and KRAS mutations have clinical utility as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive (tumor proportion score ≥1%) advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR / ALK alterations in the phase III KEYNOTE-042 trial. This retrospective exploratory analysis assessed prevalence of tTMB and STK11 , KEAP1 , and KRAS mutations determined by whole-exome sequencing of tumor tissue and matched normal DNA and their associations with outcomes in KEYNOTE-042. Clinical utility of tTMB was assessed using a prespecified cut point of 175 mutations/exome. Of 793 patients, 345 (43.5%) had tTMB ≥175 mutations/exome and 448 (56.5%) had tTMB <175 mutations/exome. No association was observed between PD-L1 expression and tTMB. Continuous tTMB score was associated with improved overall survival (OS) and progression-free survival among patients receiving pembrolizumab (Wald test, one-sided P < 0.001) but not those receiving chemotherapy (Wald test, two-sided P > 0.05). tTMB ≥175 mutations/exome was associated with improved outcomes for pembrolizumab versus chemotherapy, whereas tTMB <175 mutations/exome was not {OS: hazard ratio, 0.62 [95% confidence interval (CI) 0.48-0.80] and 1.09 (95% CI 0.88-1.36); progression-free survival: 0.75 (0.59-0.95) and 1.27 (1.04-1.55), respectively}. Improved OS [hazard ratio (95% CI)] for pembrolizumab versus chemotherapy was observed regardless of STK11 [ STK11 mutant (n = 33): 0.37 (0.16-0.86), STK11 wild-type (n = 396): 0.83 (0.65-1.05)]; KEAP1 [ KEAP1 mutant (n = 64): 0.75 (0.42-1.35), KEAP1 wild-type (n = 365): 0.78 (0.61-0.99)], or KRAS [ KRAS mutant (n = 69): 0.42 (0.22-0.81); KRAS wild-type (n = 232): 0.86 (0.63-1.18)] mutation status. tTMB with a cut point of ≥175 mutations/exome is a potential predictive biomarker for pembrolizumab monotherapy for advanced/metastatic PD-L1 tumor proportion score ≥1% NSCLC. Pembrolizumab is a standard first-line treatment in this setting regardless of STK11 , KEAP1 , or KRAS mutation status. • Pembrolizumab monotherapy is a standard first-line treatment of patients with PD-L1-positive advanced/metastatic NSCLC. • We assessed clinical utility of potential biomarkers among patients receiving pembrolizumab versus chemotherapy. • tTMB ≥175 mutations/exome was associated with improved outcomes among patients receiving pembrolizumab versus chemotherapy. • tTMB has potential clinical utility as a biomarker for pembrolizumab in first-line PD-L1-positive advanced/metastatic NSCLC. • Pembrolizumab improved overall survival versus chemotherapy regardless of STK11 , KEAP1 , or KRAS mutation status. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

3. 12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study.

Author

Reinmuth, N., Cho, B.C., Luft, A., Alexander, J.A. Alatorre, Geater, S. Lucien, Laktionov, K., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C-T., Araujo, L.H., Saito, H., Barrett, K., Lowery, C., Tattersfield, R., Peters, S., Garon, E.B., Mok, T.S.K., and Johnson, M.L.

Published
2023
Full Text
View/download PDF

4. 585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib.

Author

Mok, T.S.K., Liu, G., Nyaw, S.F., Curcio, H., Cortot, A., Kam, T.Y., Descourt, R., Chik, Y.K., Cheema, P.K., Gwinnutt, J.M., Churchill, E.N., Nyborn, J., Curran, E., Yin, Y., Chong, K., Tanaka-Chambers, Y., Kretz, J., and Cadranel, J.

Subjects
*NON-small-cell lung carcinoma, *INSERTION mutation, *EPIDERMAL growth factor receptors, *TREATMENT effectiveness
Published
2023
Full Text
View/download PDF

5. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A.

Author

Gadgeel, S.M., Mok, T.S.K., Peters, S., Nadal, E., Han, J-Y., Alatorre Alexander, J.A., Leighl, N., Sriuranpong, V., Pérol, M., Castro, G.D., de Marinis, F., Tan, D.S.W., Paul, S., Assaf, Z.J., MacLennan, M., Lohmann, T.O., Slade, M., Mathisen, M.S., Bhagawati-Prasad, V., and Dziadziuszko, R.

Subjects
*CIRCULATING tumor DNA, *NON-small-cell lung carcinoma, *BIOMARKERS, *DNA, *TUMORS
Published
2023
Full Text
View/download PDF

6. Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer.

Author

Lee, V.H.F., Mok, T.S.K., Goto, Y., Hsue, V.C.C., Yang, L., Jiang, Y., Leung, D.K.C., Lau, K.S., and Tse, P.Y.

Subjects
*LUNG cancer & genetics, *LUNG cancer treatment, *THERAPEUTIC use of monoclonal antibodies, *CELL receptors, *EPIDERMAL growth factor, *HEALTH services accessibility, *HEALTH status indicators, *MEDICAL practice, *GENETIC mutation, *POPULATION geography, *QUALITY of life, *TUMOR classification, *DISEASE management, *TREATMENT effectiveness, *DISEASE incidence
Abstract

Lung cancer is a common cancer associated with high mortality rates worldwide. Unfortunately, it usually presents at a late stage, precluding the chance of curative therapy. The discovery of oncogenic driver mutations in patients with non-small cell lung cancer over the past 20 years has led to new molecular targeted therapies that have dramatically improved treatment efficacy and quality of life. New generations of therapy that target the drug-resistant mutations have also quickly evolved, benefiting patients who are refractory or intolerant to first-line targeted therapy. Eastern patients, from Southeast Asia, Japan and China, are known to have a higher incidence of epidermal growth factor receptor mutation. Therefore, compared with the West, more patients would benefit from these recent advances. In contrast, survival of patients without driver mutations has benefited from advances in novel therapeutics, including the immune checkpoint inhibitors. The current review aims to highlight the recent developments in the management of advanced-stage non-small cell lung cancer and to compare the differences in clinical practice between Eastern and Western countries. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

8. VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo).

Author

Liu, S.V., Mok, T.S.K., Mansfield, A.S., De Boer, R.H., Losonczy, G., Sugawara, S., Krzakowski, M.J., Smolin, A., Hochmair, M.J., Garassino, M.C., Gay, C.M., Heymach, J.V., Byers, L.A., McCleland, M., Nabet, B.Y., Morris, S., Adler, L., Shames, D., and Reck, M.

Subjects
*GENE expression, *SMALL cell lung cancer, *CARBOPLATIN, *ETOPOSIDE, *CANCER patients
Published
2021
Full Text
View/download PDF

9. LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC).

Author

Mok, T.S.K., Pujol, J-L., Tsuboi, M., Lee, J., Kim, E., Leonov, O., Zhang, J., Duan, J., Lobetti-Bodoni, C., Brase, J.C., Savchenko, A., and Garrido Lopez, P.

Subjects
*NON-small-cell lung carcinoma, *NEOADJUVANT chemotherapy, *PEMBROLIZUMAB
Published
2022
Full Text
View/download PDF

10. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722.

Author

Mok, T.S.K., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H.R., Wu, Y-L., Gainor, J., Lee, S-H., Chiu, C-H., Sang-We, K., Cheng-Ta, Y., Liang, W., Wu, L., Lin, M-C., Samol, J., Zhang, X., Sylvester, J., Li, S., and Yang, J.C-H.

Subjects
*NON-small-cell lung carcinoma, *PROTEIN-tyrosine kinase inhibitors, *NIVOLUMAB, *DISEASE progression, *EPIDERMAL growth factor receptors
Published
2022
Full Text
View/download PDF

20. LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12.

Author

Barlesi, F., Yao, W., Duruisseaux, M., Doucet, L., Shi, J., Juan Vidal, O.J., Kim, Y-C., García Campelo, M.R., Azkárate Martínez, A., Lu, S., Jotte, R., Felip, E., Lo Russo, G., Reck, M., Zhang, Y., Hu, N., Michenzie, M.F., and Mok, T.S.K.

Subjects
*DOCETAXEL, *NON-small-cell lung carcinoma
Published
2024
Full Text
View/download PDF

24. The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis.

Author

Chan, O.S.H., Lee, V.H.F., Mok, T.S.K., Mo, F., Chang, A.T.Y., and Yeung, R.M.W.

Abstract

Aims Almost all patients with epidermal growth factor receptor (EGFR) mutations will develop resistance to first-line EGFR tyrosine kinase inhibitors (TKIs). The management of oligoprogression on EGFR TKI is controversial. Irradiating progressing tumours may potentially eradicate the resistant clone and allow continuation of EGFR TKI, but the clinical data remain sparse. We aimed to assess the effect of radiotherapy on survival outcomes in patients with oligoprogression in a matched-cohort study. Materials and methods This was a retrospective matched-cohort study comparing patients with EGFR mutation-positive stage IV non-small cell lung cancer receiving radiotherapy versus chemotherapy for progression. Patients in the radiotherapy group received radiotherapy (mainly stereotactic ablative radiotherapy) for oligoprogression, whereas the chemotherapy group received only systemic chemotherapy upon progression. Key prognostic factors including gender, age, performance status, time to first progression and mutation subtypes were matched. Results Twenty-five patients with oligoprogression (radiotherapy group) were identified, and a matched chemotherapy group with the same number of patients was generated. The median duration of follow-up was 24.3 and 34 months for the radiotherapy and chemotherapy groups, respectively. The median overall survival of the radiotherapy group was significantly longer than the chemotherapy group, 28.2 versus 14.7 months ( P = 0.026). The median progression-free survival (PFS) was 7.0 and 4.1 months after radiotherapy and chemotherapy, respectively ( P = 0.0017). The use of radiotherapy was an independent predictive factor of overall survival and PFS in multivariate analysis. Only one patient had ≥grade 3 toxicity after radiotherapy. The frequency of secondary T790M mutation and subsequent Osimertinib exposure were similar in both groups. Conclusion Radiotherapy may effectively extend EGFR TKI therapy for patients with oligoprogression on TKI. Improved PFS and overall survival were observed, although potential biases should not be overlooked. Further randomised studies are warranted. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

28. 507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC.

Author

Jänne, P.A., Wang, B-C., Cho, B.C., Zhao, J., Li, J., Hochmair, M.J., Peters, S., Besse, B., Kato, T., Wu, Y-L., Nguyen, D., Lin, J., Vranceanu, F., Lin, M., Fram, R.J., and Mok, T.S.K.

Subjects
*EPIDERMAL growth factor receptors, *CLINICAL trials, *NON-small-cell lung carcinoma, *CANCER chemotherapy, *METASTASIS
Published
2023
Full Text
View/download PDF

31. 362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial.

Author

Tan, A., Kim, D-W., Baisamut (Reungwetwattana), T., Yueh Ni, L., Ho, G.F., Tho, L.M., Prasongsook, N., Lee, S., Mok, T.S.K., Tan, D.S.W., and Loong, H.H.F.

Subjects
*NON-small-cell lung carcinoma, *EPIDERMAL growth factor receptors, *SUBGROUP analysis (Experimental design)
Published
2022
Full Text
View/download PDF

32. 326P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y).

Author

Cho, B.C., Luft, A., Alatorre Alexander, J.A., Lucien Geater, S., Laktionov, K., Sang-We, K., Ursol, G., Hussein, M., Lim Farah, L., Yang, C.T., Araujo, L.H., Saito, H., Reinmuth, N., Lai, Z., Mann, H., Shi, X., Peters, S., Garon, E.B., Mok, T.S.K., and Johnson, M.L.

Subjects
*OVERALL survival, *NON-small-cell lung carcinoma, *CANCER chemotherapy, *METASTASIS
Published
2022
Full Text
View/download PDF

33. LBA59 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y).

Author

Johnson, M., Cho, B.C., Luft, A., Alatorre-Alexander, J., Geater, S.L., Laktionov, K., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C.T., Araujo, L.H., Saito, H., Reinmuth, N., Lai, Z., Mann, H., Shi, X., Peters, S., Garon, E., and Mok, T.S.K.

Subjects
*OVERALL survival, *NON-small-cell lung carcinoma, *CANCER chemotherapy, *METASTASIS
Published
2022
Full Text
View/download PDF

37. 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON.

Author

Garon, E.B., Cho, B.C., Luft, A., Alatorre-Alexander, J., Geater, S.L., Trukhin, D., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C-T., Araujo, L.H., Saito, H., Reinmuth, N., Medic, N., Mann, H., Shi, X., Peters, S., Mok, T.S.K., and Johnson, M.

Subjects
*PATIENT reported outcome measures, *NON-small-cell lung carcinoma, *CANCER chemotherapy, *METASTASIS
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results